Shandra Eisenga Human Cell and Tissue Product Safety Act

Bill 118 hr 7188, also known as the Shandra Eisenga Human Cell and Tissue Product Safety Act, is a piece of legislation introduced in the US Congress. The purpose of this bill is to enhance the safety and oversight of human cell and tissue products used in medical procedures.

The bill is named after Shandra Eisenga, a patient who suffered serious health complications after receiving a contaminated human cell and tissue product during a medical procedure. The goal of the legislation is to prevent similar incidents from occurring in the future by implementing stricter regulations and oversight measures.

Some key provisions of the Shandra Eisenga Human Cell and Tissue Product Safety Act include: 1. Establishing a national registry for human cell and tissue products, which will track the distribution and use of these products to ensure they meet safety standards. 2. Requiring manufacturers of human cell and tissue products to adhere to strict quality control measures and report any adverse events or safety concerns. 3. Increasing penalties for violations of safety regulations related to human cell and tissue products. 4. Providing funding for research and development of new technologies to improve the safety and efficacy of these products. Overall, the Shandra Eisenga Human Cell and Tissue Product Safety Act aims to protect patients from the risks associated with contaminated or unsafe human cell and tissue products. By implementing stricter regulations and oversight measures, the bill seeks to improve the safety and quality of these products used in medical procedures across the United States.